Compare Airbnb, Inc. (ABNB) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Airbnb, Inc. vs Charles River Laboratories Intl. Inc — how do they compare? Airbnb, Inc. trades at $179.92 (market cap $110.76B), while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Airbnb, Inc. is far larger — about 8.2× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Airbnb, Inc. nearer its low. Which is the better fit depends on your goals.
| ABNB | CRL | |
|---|---|---|
Market Cap | $110.76B | $13.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $282.00 |
52-Week Low | $111.54 | $145.57 |
Enterprise Value | $101.19B | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABNB trades at $179.40, down 2.87% over 24 hours, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported Q2 2026 EPS of $1.37, beating expectations, and revenue growth continues with a 20.45% net income margin. Recent news highlights AI-driven growth and expansion into hotels and travel services.
Outlook is positive with strong analyst support and AI integration boosting efficiency, but high valuation ratios and competitive pressures pose risks. The consensus price target is $173.26, slightly below current price, indicating cautious optimism amid growth momentum.
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
